Helsinki, Finland

Beatriz Martins

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Valo Therapeutics Oy. Active years: 2024-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Beatriz Martins: Innovator in Cancer Therapy

Introduction

Beatriz Martins is a prominent inventor based in Helsinki, Finland. She has made significant contributions to the field of cancer therapy through her innovative research and development. Her work focuses on utilizing modified oncolytic adenoviruses to create effective treatments for cancer.

Latest Patents

Beatriz holds a patent for a cancer therapy that involves a modified oncolytic adenovirus. This invention includes a pharmaceutical composition comprising the modified virus and outlines a method for treating cancer using this approach. Her patent represents a crucial advancement in the fight against cancer, showcasing her dedication to improving patient outcomes.

Career Highlights

Beatriz is currently employed at Valo Therapeutics Oy, a company dedicated to developing novel therapies for cancer treatment. Her role at the company allows her to collaborate with other talented professionals in the field, further enhancing her contributions to cancer research.

Collaborations

Some of Beatriz's coworkers include Tuuli Ranki and Sari Pesonen. Their collaboration fosters a dynamic environment for innovation and research, enabling them to tackle complex challenges in cancer therapy together.

Conclusion

Beatriz Martins is a trailblazer in the field of cancer therapy, with her innovative patent and collaborative spirit driving advancements in treatment options. Her work at Valo Therapeutics Oy exemplifies the impact of dedicated inventors in the medical field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…